This page shows the latest Ablynx news and features for those working in and with pharma, biotech and healthcare.
dapirolizumab pegol, Ablynx’ IL-6 inhibitor vobarilizumab, and ImmuPharma’s immune modulator rigerimod.
He also bolstered the company’s pipeline with acquisitions of Ablynx and Bioverativ for 3.9bn and $11.6bn, respectively, building a franchise in rare blood diseases, but missed out to ... atopic dermatitis and asthma therapy Dupixent (dupilumab) and
Bioverativ an Ablynx last year. ... Alprolix – and the takeover of Belgian biotech Ablynx last year to claim rights to acquired thrombotic thrombocytopenic purpura (aTTP) therapy Cablivi (caplacizumab).
Prior to its takeover, Ablynx had suggested peak sales of more than 1bn were possible. ... It is the first drug to be approved for marketing based on Ablynx’s ‘nanobody’ technology, a new class of therapeutic proteins based on single-domain
at Ablynx before it was sold to Sanofi last year for $4.8bn – took over as chair of the UK biotech. ... The company has made no secret of its intention to follow an Ablynx-like path and become an integrated biotech focused on developing and
de Fougerolles, who joined the company last year from Ablynx.
More from news
Approximately 8 fully matching, plus 34 partially matching documents found.
acquisition of Belgium’s Ablynx by Sanofi.
corporate roles for Vertex and Ablynx.
bid for Ablynx in December, which the Ablynx Board rejected. Novo Nordisk's particular interest was in lead asset caplacizumab, a Nanobody therapeutic which inhibits von Willebrand factor (vWF) for the ... Acquisition company. 7, 000. Ablynx/Sanofi.
410. Ablynx. Novo Nordisk. Discovery collaboration, licence. Multi specific Nanobody drug candidates in undisclosed TA with option to expand to second Nanobody programme.
25, 000. Ablynx / Merck &Co. Collaboration. Nanobody candidates to target “immune checkpoint modulators”.
More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.
Muijrers has worked with pharmaceutical clients such as Kite Pharma, Ablynx and Juno Therapeutics, and said: “I am thrilled to join PureTech Health, one of the most exiciting and unique biopharma
He has also served on several boards including Ablynx, Evotec and Acambis.
Dr Greig has been non-executive director of Ablynx since 2012, and has been unanimously elected by the board to be the biotech’s new chairman. ... Dr Edwin Moses, chief executive officer of Ablynx, said: “We are very fortunate to have a very suitable
Ablynx, recently acquired by Sanofi, has appointed Robert Freisen to the role of chief scientific officer, who will head the biopharma’s scientific research and technology activities. ... He said: “I have long admired Ablynx and am excited to join
Biopharmaceutical group Ablynx has made some changes to its board of directors after recently declining a takeover proposal for the second time from Novo Nordisk. ... Heading up the board is Ablynx’s non-executive director Dr Bo Jesper Hensen (pictured)
More from appointments
Approximately 5 fully matching, plus 6 partially matching documents found.
We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...